Suscribirse

Analysis of differences in treating peripheral arterial disease in men and women - 14/05/25

Doi : 10.1016/j.vasdi.2025.01.126 
Pauline Duprez-Larnier a, , Olivier Espitia b , Jérôme Connault a , Marc-Antoine Pistorius a , Vianney Guardiolle c , Matthieu Wargny c , Bertrand Cariou d , Blandine Maurel-Desanlis e , Mathieu Artifoni a
a Department of Vascular Medicine, CHU of Nantes, 1, place Alexis-Ricordeau, 44000 Nantes, France 
b Department of Vascular Medicine, Nantes University, CHU of Nantes, 1, place Alexis-Ricordeau, 44000 Nantes, France 
c Inserm, CIC 1413, pôle hospitalo-universitaire 11 : santé publique, clinique des données, Nantes université, CHU de Nantes, 44000 Nantes, France 
d Department of Endocrinology-Diabetology-Nutrition, CHU of Nantes, 1, place Alexis-Ricordeau, 44000 Nantes, France 
e Department of Vascular Surgery, Nantes University, CHU of Nantes, 1, place Alexis-Ricordeau, 44000 Nantes, France 

*Corresponding author. Nantes University Hospital, 1, place Alexis-Ricordeau, 44000 Nantes, France.Nantes University Hospital1, place Alexis-RicordeauNantes44000France

Highlights

Women are more at risk of failure after lower extremity surgery in this retrospective study of 447 patients including 132 women.
This can be explained by management at a later stage of peripheral arterial disease, an older age and more distal arterial disease, but also by medical treatment that seems to differ between men and women.

El texto completo de este artículo está disponible en PDF.

Abstract

Objective

PAD is a frequent and growing pathology in recent years. Knowledge of PAD in women compared to men is surprisingly low compared to literature data concerning other cardiovascular diseases and general illnesses. For example, studies comparing endovascular or surgical revascularization in men versus women have reported conflicting results.

Methods

In this retrospective cohort study based on medical records, we included adult patients (men and women) who had been hospitalized in the vascular surgery department of Nantes University Hospital Center for PAD revascularization by angioplasty with or without stent. The primary outcome was a composite of revascularization failures, collected intraoperatively, at one month (M1) and at one year (A1). Secondary outcome included various risk factors for PAD.

Results

A total of 447 patients including 315 men and 132 women were enrolled in the trial. The prevalence of tobacco was different between the two groups with 245 men (78.0%) who were smoking or had quit smoking, while only 13 women (9.8%) were smoking and 30 (22.7%) had quit smoking. Post-surgical anticoagulant, calcium channel blocker, beta-blocker and antiplatelet drugs were similarly prescribed in men and women. Differences were found for treatment with a renin-angiotensin system inhibitor, prescribed in 48.5% in women and in 60.2% in men (P=0.028). Similarly, statin treatment was prescribed in 59.1% of women and 76.4% of men (P<0.001). The 1-month incidence of the primary-outcome was higher in women than in men (27.8% vs. 19.3%), with a risk ratio of 1.43 (95% confidence interval [CI], 0.99 to 2.06; P=0.071). At one year, we found a risk ratio of 1.13 (95% confidence interval [CI], 0.94 to 1.37; P=0.20). In multivariable regression model, the adjusted odds ratio for primary outcome was 1.65 for women/men (95% confidence interval [CI], 0.95 to 2.86; P=0.075). Finally, there were significantly more cardiovascular deaths in women than in men at one month (P=0.003) and one year (P=0.005).

Conclusions

Women are more at risk of failure after lower extremity surgery, especially in the first month. After a year of hindsight, women have more cardiovascular mortality than men. This can be explained by management at a later stage, a higher age or more distal damage, but also by differences in optimal medical treatment in men and women.

El texto completo de este artículo está disponible en PDF.

Keywords : Peripheral arterial disease, Angioplasty, Women, Long-term adverse effects, Metabolic syndrome


Esquema


© 2025  The Authors. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 50 - N° 2

P. 69-74 - avril 2025 Regresar al número
Artículo precedente Artículo precedente
  • Prognostic factors of acute pulmonary embolism in a Sub-Saharan African country: The case of Togo
  • Soulemane Pessinaba, Yaovi Mignazonzon Afassinou, Gernique Nkuitché, Mohamed Kpélafia, Komlavi Yayehd, Wiyao Dieudonné Kaziga, Ekpé Togbossi, Tcha Tchérou, Borgatia Atta, Mario Bakai, Machihude Pio, Soodougoua Baragou, Findibé Damorou
| Artículo siguiente Artículo siguiente
  • Giant cell arteritis: Diagnostic approach based on a retrospective study on 21 cases
  • Haifa Tounsi, Jaafer Aouni, Ghada Kharrat, Wafa Skouri, Sana Ferchichi, Wafa Garbouj, Sabrine Bachrouch, Manel Lajmi, Selma Dghaies, Abir Chaabene, Yassine Kaabar, Khaled Bouzaidi, Raja Amri, Zeineb Alaya

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.